VC  Lumira Ventures

https://www.lumiraventures.com/





     Office Locations:

303 Wyman Street, Suite 300
Waltham, MA 02451
Phone: 781-530-3868
Fax: 253-484-4262

Get all office locations for this firm with a National Database subscription.
 

Stages:

  • Expansion


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    Lumira Ventures invests in transformative biopharmaceutical, medical device and digital health companies located in North America. The firm's history goes back to 1989 when the company was established as MDS Capital Corp. The company changed its name to Lumira Capital in September 2007 as part of a corporate repositioning to build on its strength in the North American health and life science sector. Typically, Lumira's initial investment size is $5 to $10 million, and the firm concentrates its investments in the U.S. and Canada. Over more than two decades, the firm has invested over $1B via multiple investment funds in order 200 healthcare companies. $6+ billion in capital has been raised by portfolio companies.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Baye Galligan MA Director of Research
    Beni Rovinski PhD Managing Director
    Brent Norton MD, MBA, ICDD Venture Partner
    Daniel Hetu MD, MBA Managing Director
    David Novak MSc Venture Partner

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      11/04/2024


      AXONIS Therapeutics


      MA


      $115,000,000


      Series A


      10/23/2024


      Alpha-9 Oncology


      MA


      $175,000,000


      Series C


      09/11/2024


      SpectraWAVE


      MA


      $50,000,000


      Series B


      08/15/2024


      HistoSonics


      


      $102,000,000


      Series D


     

    Portfolio companies include:


      Alpha-9 Oncology
        web link


      Antios Therapeutics
        web link


      Arclight Therapeutics


      AXONIS Therapeutics
        web link


      Bardy Diagnostics
        web link


      Cardiac Dimensions
        web link


      Corvia


      Cour


      Cyrano Therapeutics


      Deka Biosciences
        web link


      HistonSonics
        web link


      HistoSonics


      IMV


      Iterion Therapeutics
        web link


      Nocion Therapeutics


      Notch Therapeutics


      PIC Therapeutics
        web link


      SpectraWAVE
        web link


      Thryv Therapeutics


      Transposon Therapeutics


      Xylo Cor Therapeutics


     

    Recent News: